Ranbaxy Laboratories Ltd (RANB.NS)
|Market Cap (Mil.):||Rs238,507.50|
|Shares Outstanding (Mil.):||424.01|
ZURICH - Swiss drugmaker Novartis posted a quarterly rise in sales that missed expectations and said it would focus on eking out gradual cost savings to boost margins as it prepares a radical business overhaul.
* Move aimed towards making drugs more affordable in India
MUMBAI, July 14 - India's pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.
* BSE index gains 0.15 pct; NSE ends 0.21 pct higher * Century Textile rallies after investor Damani buys stake * Aban likely to launch up to $150 mln share sale on Friday - sources * Ranbaxy gets FDA approval for Novartis's Diovan generic By Abhishek Vishnoi MUMBAI, June 27 - Indian shares rose on Friday as defensive stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories jumped on the U.S. regulator's approval for a key drug while IT stocks gained
WASHINGTON/MUMBAI - India's Ranbaxy Laboratories Ltd has received approval from the U.S. Food and Drug Administration (FDA) to launch a cheaper copy of Novartis AG's blood pressure pill Diovan, bolstering its outlook after a raft of regulatory bans for poor production quality at its India facilities dented investor sentiment.
* Drug could add about $200 mln to Ranbaxy sales - analyst
MUMBAI - India's Ranbaxy Laboratories rose 5.8 percent in early trading after the U.S. Food and Drug Administration said on Thursday it had approved the company's generic version of Novartis AG's blood pressure drug Diovan.
June 26 - The U.S. Food and Drug Administration said on Thursday it has approved Ranbaxy Laboratories Ltd's generic version of Novartis AG's blood pressure drug Diovan.
Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Aby Jose Koilparambil in Bangalore)
- European regulators said on Thursday they have completed their assessment of drug manufacturing violations at Ranbaxy Laboratories Ltd's facility in Toansa, India, and although deficiencies were found, they pose no risk to public health.
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Ranbaxy Laboratories Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: BuySellSignals Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.